Bioactive compounds from Okinawan marine cyanobacteria

Toshiaki Teruya, Osamu Ohno, Kiyotake Suenaga

Research output: Chapter in Book/Report/Conference proceedingChapter


Natural products, especially those from terrestrial plants and microbes, have been the most productive source of drug molecules over the years, and pharmacologically active compounds from plants and microbes continue to play an important role in developing new investigational drugs (Butler 2008; Newman and Cragg 2007). However, much attention has recently been given to marine organisms due to their remarkable biological activities (Molinski et al. 2009). In particular, cyanobacteria are prolific producers of biologically active compounds (Gerwick, Tan, and Sitachitta 2001). Cyanobacteria have been recognized as a source of pharmaceutical lead compounds (Tan 2007), for example, TZT-1027, a synthetic dolastatin 10 analog, is currently being evaluated in phase II clinical trials in the United States (Yamamoto et al. 2009). Dolastatin 10 was originally isolated from the sea hare Dolabella auricularia and has been subsequently isolated from marine cyanobacterium (Luesch et al. 2001; Pettit et al. 1987). Cryptophycin-309 and cryptophycin-249, which are derivatives of the terrestrial cyanobacterial peptide cryptophycin-1, have undergone preclinical efficacy studies (Liang et al. 2005).

Original languageEnglish
Title of host publicationMarine Pharmacognosy
Subtitle of host publicationTrends and Applications
PublisherCRC Press
Number of pages5
ISBN (Electronic)9781439892305
ISBN (Print)9781439892299
Publication statusPublished - 2012 Jan 1

ASJC Scopus subject areas

  • General Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • General Agricultural and Biological Sciences
  • General Chemistry


Dive into the research topics of 'Bioactive compounds from Okinawan marine cyanobacteria'. Together they form a unique fingerprint.

Cite this